Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brand Name Review By FDA: Predictability Returns To Process

Executive Summary

CDER now granting 86% of sponsors’ preferred proprietary names prior to launch – a significant improvement over just five years ago that seems driven in part by several new guidance documents.

Advertisement

Related Content

FDA Rejecting Fewer Proprietary Names
What’s In A Name? Janssen’s Loss Of Sovriad Was Gilead’s Gain With Sovaldi
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions
The Name of the Game: Adjusting to a Tougher FDA Brand Name Review Process

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register